Akbay, Esra A.
The University of Texas Southwestern Medical Center
8 papers on CoChatORCID 0000-0002-4149-2529
Most cited papers
- Verified
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications
Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology
Cited by 1,580
- Verified
STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment
Koyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research
Cancer Immunotherapy and BiomarkersImmune cells in cancer
Cited by 640
- Verified
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2
Zhang, H., Fillmore Brainson, C., Koyama, S., Redig, A. J., Chen, T., Li, S., Gupta, M., Garcia-de-Alba, C., Paschini, M., Herter-Sprie, G. S., et al. (2017) · Nature Communications
Epigenetics and DNA MethylationCancer Cells and Metastasis
Cited by 127
- Verified
Development of Selective Covalent Janus Kinase 3 Inhibitors
Tan, L., Akahane, K., McNally, R., Reyskens, K. M. S. E., Ficarro, S. B., Liu, S., Herter-Sprie, G. S., Koyama, S., Pattison, M. J., Labella, K., et al. (2015) · Journal of Medicinal Chemistry
Cytokine Signaling Pathways and InteractionsHeterocyclic Compound Synthesis and Bioactivity
Cited by 122
- Verified
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells
Li, H., Liu, Z., Liu, L., Zhang, H., Han, C., Girard, L., Park, H., Zhang, A., Dong, C., Ye, J., et al. (2022) · Cell Reports Medicine
Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology
Cited by 102
- Verified
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer
Gong, K., Guo, G., Panchani, N., Bender, M. E., Gerber, D. E., Minna, J. D., Fattah, F., Gao, B., Peyton, M., Kernstine, K., et al. (2020) · Nature Cancer
Lung Cancer Treatments and Mutationsinterferon and immune responses
Cited by 92
- Verified
Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in murine Kras mutant lung cancer
Choi, H., Deng, J., Li, S., Silk, T., Dong, L., Brea, E. J., Houghton, S., Redmond, D., Zhong, H., Boiarsky, J., et al. (2019) · Cell Reports
Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways
Cited by 72
- Verified
Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer
Li, S., Liu, S., Deng, J., Akbay, E. A., Hai, J., Ambrogio, C., Zhang, L., Zhou, F., Jenkins, R. W., Adeegbe, D. O., et al. (2018) · Clinical Cancer Research
Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways
Cited by 67
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free